Photo credit: www.investing.com

Relief Therapeutics Highlights New Advances in PKU Management

GENEVA, SWITZERLAND / ACCESSWIRE / October 29, 2024 / Relief Therapeutics Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY), a biopharmaceutical company focused on developing innovative treatments for specialized, rare conditions, has released a new Plain Language Summary in Future Rare Diseases. This summary emphasizes the potential benefits of PKU GOLIKE ® in managing phenylketonuria (PKU). The article, titled “The Benefits of a Prolonged-Release Protein Substitute with Similarities to Natural Proteins as a Treatment for Phenylketonuria,” was collaboratively written by PKU specialists and patient associations, making complex clinical findings more accessible to a wider audience.

This summary distills the findings of a clinical study that compares PKU GOLIKE ®, a prolonged-release amino acid formulation developed by Relief, with traditional amino acid products. Key findings indicate that both formulations deliver equivalent total amino acid levels; however, PKU GOLIKE ® exhibits a more natural absorption pattern, mimicking the gradual release of proteins found in whole food sources. This sustained release is particularly advantageous for individuals managing PKU, as it helps maintain metabolic stability through consistent amino acid intake.

The role of Plain Language Summaries is crucial, as they enhance the understanding of scientific studies among the general public. Such summaries not only spotlight the significance of research findings but also encourage active engagement from patients and their families. Patrizia Marzorati, Head of Medical Affairs at Relief, emphasized the company’s commitment to patient-centric values: “Our core value as a rare disease pharma company is patient centricity, putting patients at the heart of drug development. Creating accessible information and resources that meet patient needs is one of our strategies to foster inclusion. By helping patients and caregivers understand scientific information, we aim to support both compliance and acceptance of dietary management in PKU.”

About PKU GOLIKE ®

PKU GOLIKE products qualify as Foods for Special Medical Purposes (FSMPs) intended to aid in the dietary management of PKU for both children and adults. Utilizing Relief’s proprietary Physiomimic Technology drug delivery platform, PKU GOLIKE products are the first of their kind to offer a prolonged-release format. The unique coating of these products promotes the physiological absorption of amino acids akin to the natural proteins found in food while effectively masking the unpleasant taste and smell often associated with amino acids. In the U.S., PKU GOLIKE products are marketed by Eton Pharmaceuticals Inc. under an exclusive licensing agreement with Relief, while they are available in various European markets and select countries worldwide through partnerships and distribution agreements.

About Relief Therapeutics

Relief Therapeutics is a commercial-stage biopharmaceutical firm dedicated to improving treatment options and delivering clinical benefits for patients with rare and specialty diseases. The company maintains a diverse portfolio that combines marketed, revenue-generating products with proprietary, globally patented TEHCLO and Physiomimic technologies, alongside a focused clinical development pipeline featuring low-risk assets in three principal therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. Additionally, Relief is actively involved in the commercialization of several legacy products through strategic licensing and distribution agreements. The company is headquartered in Geneva and is listed on the SIX Swiss Exchange (RLF) and the OTCQB (RLFTF, RLFTY).

Disclaimer
This article includes forward-looking statements that are subject to risks and uncertainties. These risks may affect Relief’s ability to meet its corporate, development, and commercial objectives. Factors detailed in Relief’s filings with the SIX Swiss Exchange and the U.S. Securities and Exchange Commission (SEC) could materially impact the company’s actual outcomes. For additional details, Relief’s SEC filings can be found on the SEC EDGAR database at www.sec.gov. The company does not commit to updating the information provided herein, which is accurate only as of the publication date.

Source
www.investing.com